| Literature DB >> 17697748 |
Verena Stresing1, Florence Daubiné, Ismahène Benzaid, Hannu Mönkkönen, Philippe Clézardin.
Abstract
Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone destruction. We review here preclinical evidence that bisphosphonates also exert direct antitumour effects and antiangiogenic properties. Furthermore, we describe new insights on how bisphosphonates may act synergistically in combination with antineoplastic drugs or gammadelta T cells to exhibit antitumour activity. These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17697748 DOI： 10.1016/j.canlet.2007.07.007
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679